US Venture Partners, a venture capital investment firm, led a $16m Series A round in Luminopia, a commercial-stage company pioneering a new class of treatments for neuro-visual disorders, with participation from Broadfin Advisors, ShangBay Capital and Vertical Group. "US Venture Partners is excited to support the team at Luminopia and be part of their journey as they seek to transform care and improve patient outcomes in an area of medicine that has seen relatively little innovation," Casey Tansey, US Venture Partners General Partner.